Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Nu.Q® Cancer White Paper: Lung cancer: hope of a brighter tomorrow

Thursday, March 20, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Volition has released a new white paper discussing the role of epigenetics in lung cancer screening and diagnosis. The document emphasizes the potential of the Nu.Q® Cancer Test to enhance current diagnostic methods. It aims to provide deeper insights into the necessity of lung cancer screening and the future of cancer diagnostics.
Price reaction · baseline $11.14 (2025-03-19 close) · hit pre-market · 3 other VNRX headline(s) in the window, move may be shared
day 0 close
-2.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • The white paper explores innovative approaches to lung cancer screening.
  • It highlights the potential of the Nu.Q® Cancer Test in improving diagnosis.
  • The focus on epigenetics could lead to significant advancements in cancer research.

Full Press Release Details

Our new White Paper is a deep dive into the science of epigenetics, and its potential to reveal deep insights into the need for lung cancer screening, how lung cancer is currently diagnosed, how it could be diagnosed using Volition’s Nu.Q® Cancer Test.

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the focus of the new white paper?

The white paper focuses on the science of epigenetics and its role in lung cancer screening.

How does the Nu.Q® Cancer Test improve diagnosis?

The Nu.Q® Cancer Test aims to enhance current lung cancer diagnostic methods.

What insights does the paper provide?

It provides insights into the necessity of lung cancer screening and potential advancements.

Who published the white paper?

The white paper was published by Volition.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare lung cancer Nu.Q® Cancer Test epigenetics diagnosis Volition
Last updated: Mar 20, 2025

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk